Skip to main content
Glama

Canada Drug Product Lookup MCP

Server Details

Look up any Canadian drug product by brand name or DIN. Free drug_search tool.

If you are the author of this connector, you can claim ownership by verifying the domain or GitHub account it belongs to. Claimed connector authors can inspect health checks, view analytics, and manage their listing.
Status
Healthy
Last Tested
Transport
Streamable HTTP · MCP 2025-03-26
URL
Repository
donniertf-hub/uk-mcp-fleet
GitHub Stars
0

TDQS

B3.1/5.0

Scored across 3 tools

Disambiguation4/5

Each tool targets a different retrieval shape: drug_search is name-based discovery, din_profile is a full single-record detail fetch, and batch_din_check is a bulk status sweep. The only friction is that batch_din_check (status only) overlaps with running din_profile across multiple DINs, so an agent may occasionally pick the wrong one for small batches.

Naming Consistency3/5

All names are snake_case, but the ordering conventions differ: din_profile and drug_search are noun-first while batch_din_check is modifier-noun-verb. The 'FREE'/'PRO' prefixes in descriptions help, but the names themselves don't telegraph a consistent verb_noun pattern.

Tool Count4/5

Three tools cover the practical entry points (name lookup, DIN detail, bulk DIN status) without redundancy. It is on the thin side, but each tool has a clear reason to exist.

Completeness3/5

Brand-name and DIN lookups are covered, but there is no ingredient-based search, no reverse lookup by ATC class or company, and drug_search is capped at top 5 with no documented pagination or refinement path. Agents doing non-brand-driven discovery will hit dead ends.

Available Tools

3 tools
batch_din_checkCInspect

PRO. Check up to 50 DINs: brand, company and current marketing status.

NameRequiredDescriptionDefault
dinsYes
access_tokenNoSubscriber token from /success (or Authorization: Bearer)

TDQS

C2.9/5.0
Behavior2/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

No annotations are present, so the description carries the full disclosure burden. The 'PRO' prefix hints at a paid/subscriber tier (consistent with the access_token param), but there is no mention of auth failure behavior, rate limits, partial-failure semantics for a batch of up to 50, or whether the call is read-only.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

A single compact sentence with the batch limit and payload fields front-loaded; nothing is wasted. The opaque 'PRO.' prefix is the only element that does not clearly earn its place.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness3/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description usefully names the three returned fields, but a batch tool of this shape should also cover partial results and the subscriber/access requirement. Adequate for a simple read-style lookup, incomplete around failure modes.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is 50%: access_token is documented in the schema as the subscriber token from /success or a Bearer header. The description adds the cardinality limit of 50 to the otherwise undocumented 'dins' array, which is genuine value beyond the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose4/5

Does the description clearly state what the tool does and how it differs from similar tools?

States a specific verb and resource ('Check ... DINs') and enumerates the returned fields (brand, company, marketing status), so an agent knows exactly what it gets. It does not distinguish itself from the sibling din_profile, so it stops short of a 5.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines2/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The 'up to 50 DINs' phrasing implies a batched use case, but the description never says when to choose this over din_profile or drug_search, nor what happens with invalid or over-limit DINs. Sibling routing is left entirely to inference.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

din_profileBInspect

PRO. Full profile for a DIN: ingredients and strengths, marketing status, schedule, route, dosage form and ATC class.

NameRequiredDescriptionDefault
dinYes
access_tokenNoSubscriber token from /success (or Authorization: Bearer)

TDQS

B3.2/5.0
Behavior3/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

With no annotations, the description carries the full burden. It usefully enumerates the returned profile fields and implies a read-style lookup, but it does not explicitly state read-only behavior, authorization requirements, error behavior, or what 'PRO.' means.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is a compact single sentence that efficiently lists the main profile contents. The leading 'PRO.' is cryptic and slightly reduces front-loading quality, but there is no wasted text.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness3/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a simple two-parameter lookup with no output schema, the description gives a useful content overview. It still leaves gaps around DIN format, explicit read-only/auth behavior, and the meaning of 'PRO.', so it is adequate but not complete.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters2/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema coverage is only 50%, and the 'din' parameter has no schema description. The tool description says only 'for a DIN' and does not explain the DIN format or requirements; the access_token parameter is documented in the schema but not elaborated in the description.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose4/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a clear resource and content set: a full profile for a DIN including ingredients, strengths, status, schedule, route, dosage form, and ATC class. It does not distinguish this tool from siblings such as drug_search or batch_din_check, so it falls short of a 5.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines3/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Use is implied by 'Full profile for a DIN' when an agent already has a DIN and needs comprehensive details. However, there is no explicit when-to-use guidance, no exclusions, and no comparison to the sibling tools.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Tool Schema Changelog

Recent tool additions, removals, and schema changes observed during successful MCP inspections.

  1. 3 tool updates
    • First observedbatch_din_check
    • First observeddin_profile
    • First observeddrug_search

Related MCP Connectors

Related MCP Servers

  • A
    license
    Not graded
    quality
    B
    maintenance
    Enables querying the Health Canada Drug Product Database for approved drugs, including brand names, DINs, active ingredients, strengths, dosage forms, routes, and market status.
    6 npm
    MIT
  • F
    license
    A
    quality
    D
    maintenance
    Enables querying the Health Canada Drug Product Database for information on approximately 47,000 approved drugs, including human pharmaceuticals, biologics, veterinary drugs, radiopharmaceuticals, and disinfectants.
    15
    2
    -
  • A
    license
    Not graded
    quality
    D
    maintenance
    Enables drug safety, interactions, adverse events, and regulatory data queries using free sources like DrugBank, WHO, FDA FAERS, and more. Provides tools for checking drugs, interactions, adverse events, and searching across pharmaceutical databases.
    MIT
  • A
    license
    B
    quality
    D
    maintenance
    Provides access to the official FDA DailyMed database for comprehensive drug information, including drug labels, NDC codes, RxNorm mappings, pharmacologic classifications, and FDA application numbers through natural language queries.
    28
    3
    MIT
Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.